Ptc Therapeutics Stock Cash And Equivalents
| PTCT Stock | USD 43.23 0.34 0.79% |
PTC Therapeutics fundamentals help investors to digest information that contributes to PTC Therapeutics' financial success or failures. It also enables traders to predict the movement of PTC Stock. The fundamental analysis module provides a way to measure PTC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PTC Therapeutics stock.
PTC | Cash And Equivalents |
PTC Therapeutics Company Cash And Equivalents Analysis
PTC Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current PTC Therapeutics Cash And Equivalents | 288.43 M |
Most of PTC Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PTC Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
PTC Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for PTC Therapeutics is extremely important. It helps to project a fair market value of PTC Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since PTC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PTC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PTC Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
PTC Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, PTC Therapeutics has 288.43 M in Cash And Equivalents. This is 64.86% lower than that of the Biotechnology sector and 35.49% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 89.33% higher than that of the company.
PTC Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PTC Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PTC Therapeutics could also be used in its relative valuation, which is a method of valuing PTC Therapeutics by comparing valuation metrics of similar companies.PTC Therapeutics is currently under evaluation in cash and equivalents category among its peers.
PTC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of PTC Therapeutics from analyzing PTC Therapeutics' financial statements. These drivers represent accounts that assess PTC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PTC Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.8B | 4.0B | 2.8B | 2.7B | 2.1B | 1.3B | |
| Enterprise Value | 2.5B | 4.2B | 2.5B | 3.0B | 3.7B | 3.9B |
PTC Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, PTC Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to PTC Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
PTC Fundamentals
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.0515 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 2.72 B | ||||
| Shares Outstanding | 77.13 M | ||||
| Shares Owned By Insiders | 2.34 % | ||||
| Shares Owned By Institutions | 97.66 % | ||||
| Number Of Shares Shorted | 4.89 M | ||||
| Price To Earning | (5.67) X | ||||
| Price To Book | 1,743 X | ||||
| Price To Sales | 3.70 X | ||||
| Revenue | 937.82 M | ||||
| Gross Profit | 2.63 M | ||||
| EBITDA | (330.34 M) | ||||
| Net Income | (626.6 M) | ||||
| Cash And Equivalents | 288.43 M | ||||
| Cash Per Share | 4.01 X | ||||
| Total Debt | 2.23 B | ||||
| Current Ratio | 1.23 X | ||||
| Book Value Per Share | (13.70) X | ||||
| Cash Flow From Operations | (158.42 M) | ||||
| Short Ratio | 5.83 X | ||||
| Earnings Per Share | (5.94) X | ||||
| Price To Earnings To Growth | 0.81 X | ||||
| Target Price | 45.0 | ||||
| Number Of Employees | 988 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 3.33 B | ||||
| Total Asset | 1.9 B | ||||
| Retained Earnings | (3.28 B) | ||||
| Working Capital | 615.53 M | ||||
| Current Asset | 355.95 M | ||||
| Current Liabilities | 45.39 M | ||||
| Net Asset | 1.9 B |
About PTC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.